• KOL
    • Prostate Cancer
    • Patrick Craig Walsh
    • PATRICK CRAIG Walsh: Influence Statistics

      PATRICK CRAIG Walsh

      PATRICK CRAIG Walsh

      Show email address

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA | Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      PATRICK CRAIG Walsh:Expert Impact

      Concepts for whichPATRICK CRAIG Walshhas direct influence:Prostate cancer,Radical prostatectomy,Specific antigen,Pathological stage,Prostate specific,Biochemical recurrence,Gleason score,Androgen receptors.

      PATRICK CRAIG Walsh:KOL impact

      Concepts related to the work of other authors for whichfor which PATRICK CRAIG Walsh has influence:Prostate cancer,Specific antigen,Active surveillance,Gleason score,Benign prostatic hyperplasia,Biochemical recurrence,Prostatic neoplasms.

      KOL Resume for PATRICK CRAIG Walsh

      Year
      2021

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA

      2020

      Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

      2019

      Department of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, MD.

      2018

      Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland

      2017

      The Johns Hopkins University School of Medicine, Baltimore, MD;

      James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA

      2016

      James Buchanan Brady Urological Institute, The Johns Hopkins Hospital and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, and Departments of Anatomy and Embryology, and Urology, University of Leiden, Leiden, The Netherlands.

      Department of Urology The Johns Hopkins Medical Institutions Baltimore MD USA

      2015

      James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland

      2014

      Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

      Duke University Medical Center, Durham, North Carolina (SJF)

      Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea

      2013

      The Johns Hopkins Medical Institutions and The James Brady Buchannan Urological Institute Department of Urology Baltimore MD USA

      Baltimore, MD

      2012

      James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA

      Johns Hopkins Hospital, Department of Urology, 600 N. Wolfe St./Park 224, Baltimore, MD 21287‐2101.

      Founders Professor of Urology, Perelman School of Medicine, University of Pennsylvania; Chief of Urology, Penn Medicine/University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

      Chairman, Glickman Urological Institute, Cleveland Clinic Foundation; Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

      Chairman and Waldbaum-Gardner Distinguished Professor, Smith Institute for Urology, Hofstra North Shore–LIJ School of Medicine, New York, New York

      2011

      Affiliations of authors: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (CEJ, AMM, CM, EAP); James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD (EBH, MH, PCW, EAP); Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD (EAP)

      The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland

      Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA

      2010

      Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland

      Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD 21205;

      2009

      Johns Hopkins University, Baltimore, MD, USA

      Urology and

      2008

      Brady Urological Institute (Drs Trock, Han, Partin, and Walsh and Ms Humphreys) and Department of Radiation Oncology and Molecular Radiation Sciences (Dr DeWeese), Johns Hopkins University School of Medicine, Baltimore, Maryland

      2007

      James Buchanan Brady Urological Institute, the Sidney Kimmel Comprehensive Cancer Center, the Department of Urology, Radiation Oncology and Molecular Radiation Sciences, and Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USA.

      Division of Urologic Surgery and Duke Prostate Center, Departments of Surgery and Pathology, Duke University School of Medicine Durham, NC

      and The Biostatistics Core, University of Southern California, Keck School of Medicine at Childrens Hospital Los Angeles, Los Angeles, CA

      Department of Surgery, Veterans Administration Medical Center Durham

      2006

      Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe St. Baltimore, Maryland 21287-2101

      Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland

      Johns Hopkins University School of Medicine, Baltimore, MD

      2005

      From the Department of Pathology (TT, HA, JIE) and Department of Urology (DJH, BT, PCW, JIE), The Johns Hopkins Hospital, Baltimore, Maryland, and the Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya, Japan (TT)

      National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland

      The James Buchanan Brady Urological Institute (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and the Departments of Urology (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and Oncology (Dr Eisenberger), The Johns Hopkins Medical Institutions, Baltimore, Md, and The Biostatistics Core, University of Southern California, Keck School of Medicine at Childrens Hospital Los Angeles, Los Angeles (Dr Dorey).

      Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which PATRICK CRAIG Walsh is among the top experts in the world.
      Concept World rank
      2 distant metastases #1
      prostate disease control #1
      volume 4 years #1
      young pca #1
      preservation urinary control #1
      prostatic tissue finding #1
      curable cancers younger #1
      prostatectomy serum #1
      1974 anatomic observations #1
      steroid specificities cytosol #1
      cytosol seminal vesicle #1
      increase daily rate #1
      human prostatic hyperplasis #1
      postoperative methylprednisolone #1
      degree prostate cancer #1
      tumescence response stimulation #1
      gene early age #1
      progression 8 tumors #1
      candidate cent #1
      hopkins experience #1
      erections electrical stimulation #1
      bph volume #1
      androgen receptors bph #1
      exploration 6 miu #1
      pcsm psm #1
      germinal epithelium fsh #1
      radical prostatectomy 1916 #1
      biochemical recurrence predictors #1
      periprostatic tissue cent #1
      17 decrease #1
      inguinal hernias rrp #1
      radical cystoprostatectomy injury #1
      benign hyperplastic prostates #1
      pt2a disease tumor #1
      multiple variables response #1
      dysgenetic male #1
      prostate established bph #1
      biochemical recurrence 1997 #1
      sexual function cent #1
      ileus discharge #1
      radical prostatectomy disease #1
      forecasting humans korea #1
      excision neurovascular bundles #1
      prostates groups #1
      anorchism boys #1
      psadt 75 months #1
      bothersome bph #1
      epithelial weight testosterone #1
      total gland size #1
      ultrasound retroperitoneal fibrosis #1
      Sign-in to see all concepts, it's free!

      Prominent publications by PATRICK CRAIG Walsh

      KOL-Index: 24001

      OBJECTIVES: To determine the clinical significance of Gleason score 3+4 versus 4+3 on radical prostatectomy.

      METHODS: Of 2390 men who underwent radical prostatectomy by a single surgeon, 570 had Gleason score 7 tumors without lymph node metastasis, seminal vesicle invasion, or tertiary Gleason pattern 5. Patients were evaluated for biochemical recurrence (prostate-specific antigen progression) and distant metastases.

      RESULTS: Eighty percent of patients had Gleason score 3+4, 20% had 4+3. ...

      Known for Gleason Score | Radical Prostatectomy | 3 4 | Prognostic Significance | 7 Tumors
      KOL-Index: 19106

      CONTEXT: Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the subgroup of men most likely to benefit.

      OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups ...

      Known for Salvage Radiotherapy | Specific Survival | Prostate Cancer | Biochemical Recurrence | Hormonal Therapy
      KOL-Index: 18544

      CONTEXT: The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.

      OBJECTIVE: To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.

      DESIGN: Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech ...

      Known for Prostate Cancer | Percentage Free Psa | Benign Prostatic Disease | Specific Antigen | Unnecessary Biopsies
      KOL-Index: 17030

      The usefulness of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade in predicting final pathological stage in patients with adenocarcinoma of the prostate remains controversial. To determine the predictive value of these 3 preoperative variables we reviewed 275 patients with clinically localized disease who were treated between April 1982 and February 1986. All patients were examined preoperatively and subsequently were operated upon by 1 urologist. Serum ...

      Known for Gleason Grade | Clinical Stage | Acid Phosphatase | Capsular Penetration | Serum Prostatic
      KOL-Index: 17013

      BACKGROUND: Two genes responsible for hereditary breast cancer (BRCA1 and BRCA2) have been identified, and predisposing mutations identified. Several studies have provided evidence that germline mutations in BRCA1 and BRCA2 confer an increased risk of prostate cancer. Based on these findings, one might expect to find an increased frequency of mutations in these genes in family clusters of prostate cancer. The Ashkenazi Jewish population is unique in that it has an approximate 2% ...

      Known for Brca2 Mutations | Prostate Cancer | Brca1 Genes | Ashkenazi Jewish | Increased Frequency
      KOL-Index: 16998

      WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The Gleason scoring system is a well-established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades - most recently by the International Society of Urological Pathology (ISUP) in 2005 - have attempted to improve the correlation between biopsy and radical prostatectomy Gleason sum and better stratify patients to predict clinical outcomes. Based on ...

      Known for Gleason Grade | International Society | Positive Cores | Radical Prostatectomy Rp | Urological Pathology
      KOL-Index: 16208

      OBJECTIVES: To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease.

      METHODS: We identified 320 men with Gleason score 7 tumors on prostate biopsy treated with radical prostatectomy between 1991 and 2001 by a single surgeon. None of these patients had received neoadjuvant or adjuvant hormonal therapy or radiotherapy. The chi-square test and Kaplan-Meier method were used to ...

      Known for Gleason Pattern | Needle Biopsy | Radical Prostatectomy | Score 7 | Biochemical Recurrence
      KOL-Index: 16113

      OBJECTIVES: Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, we compared these methods for their utility in cancer detection and their ability to predict pathologic stage after radical prostatectomy in patients with clinically localized, Stage T1c cancer.

      METHODS: Seven hundred seventy-three men (379 with prostate ...

      Known for Cancer Detection | Psa Density | Percent Free | Age Specific | Radical Prostatectomy
      KOL-Index: 16092

      We review the pathological findings of impalpable prostate cancer detected by transurethral resection (stages T1a and T1b) and needle biopsy (stage T1c). The short-term (4 years) and long-term (8 to 10 years) natural histories of untreated stage T1a prostate cancer are examined, as are options to follow patients expectantly. The findings on radical prostatectomy for stages T1a and T1b disease are reviewed and compared. Of the 64 cases of stage T1a disease 13 (20%) showed substantial ...

      Known for Needle Biopsy | Transurethral Resection | Stages T1a | Radical Prostatectomy | Prostate Cancer
      KOL-Index: 16013

      To evaluate the usefulness of serum prostate specific antigen in the preoperative staging of prostate cancer we examined tumor volume and differentiation, as well as benign prostatic hyperplasia volume to determine their influence on serum antigen levels. Serum prostate specific antigen was measured in 350 men with clinically localized prostate cancer and preoperatively in 72 men with documented benign prostatic hyperplasia. Although the mean antigen levels increased with advancing ...

      Known for Tumor Volume | Benign Hyperplasia | Prostate Specific | Pathological Stage | Antigen Levels
      KOL-Index: 15815

      Objective. —To combine the clinical data from 3 academic institutions that serve as centers of excellence for the surgical treatment of clinically localized prostate cancer and develop a multi-institutional model combining serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score to predict pathological stage for men with clinically localized prostate cancer.Design. —In this update, we have combined clinical and pathological data for a group of 4133 men treated by ...

      Known for Pathological Stage | Gleason Score | Localized Prostate Cancer | Seminal Vesicle Involvement | Nomograms Probability
      KOL-Index: 15665

      PURPOSE: The accurate prediction of pathological stage of prostate cancer using preoperative factors is a critical aspect of treatment. In 1997 Partin et al published tables predicting pathological stage using clinical stage, Gleason score and prostate specific antigen (PSA). We tested the validity of the Partin tables.

      MATERIALS AND METHODS: From 1990 to 1996 inclusively 5,780 patients underwent bilateral pelvic lymphadenectomy and radical prostatectomy for prostate cancer at the Mayo ...

      Known for Pathological Stage | Partin Tables | Prostate Cancer | Neoplasms Roc | Gleason Score

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA | Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA | Department of Urology and the James Buchanan Brady Urologic Institute,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.